Compare Medpace Holdings Inc (MEDP) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Uranium Energy Corp — how do they compare? Medpace Holdings Inc trades at $532.3 (market cap $15.35B), while Uranium Energy Corp trades at $9.37 (market cap $4.59B). The key difference: Medpace Holdings Inc is far larger — about 3.3× Uranium Energy Corp's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| MEDP | UEC | |
|---|---|---|
Market Cap | $15.35B | $4.59B |
Sector | Technology | Energy |
52-Week High | $620.59 | $20.14 |
52-Week Low | $308.88 | $8.00 |
Enterprise Value | $14.82B | $4.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $534.49, down 0.6% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.83. Recent quarters have consistently beaten EPS estimates, and 2026 forecasts project revenue growth to $2.7B. News highlights focus on CRO demand shifts and a class action lawsuit filed in June 2026.
Outlook remains positive given earnings momentum and sector demand, but risks include legal overhangs and high valuation multiples. Analyst consensus is mixed with a $497 price target below current levels, suggesting cautious optimism amid near-term headwinds.
Uranium Energy Corp (UEC) trades at $9.40, up 1.29% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a net loss of $87.66 million on $66.84 million revenue for 2025, with a negative net margin of -513.24% in 2026. Recent news highlights volatility tied to earnings misses and strategic positioning in the uranium sector, while analyst consensus remains strongly bullish with 87.5% buy ratings.
UEC's outlook hinges on execution of its in-situ recovery platform and uranium price trends, offering growth potential in nuclear energy demand. Key risks include persistent losses, high valuation multiples, and operational delays. The stock presents a speculative opportunity with significant upside if production ramps successfully, balanced by substantial financial and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
